Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
| Title: | Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. |
|---|---|
| Authors: | Athyros VG; Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, 49 Konstantinoupoleos St, Thessaloniki, 546 42, Greece. athyros@med.auth.gr; Mikhailidis DP; Papageorgiou AA; Mercouris BR; Athyrou VV; Symeonidis AN; Basayannis EO; Demitriadis DS; Kontopoulos AG |
| Source: | Current medical research and opinion [Curr Med Res Opin] 2002; Vol. 18 (8), pp. 499-502. |
| Publication Type: | Comparative Study; Journal Article |
| Language: | English |
| Journal Info: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 0351014 Publication Model: Print Cited Medium: Print ISSN: 0300-7995 (Print) Linking ISSN: 03007995 NLM ISO Abbreviation: Curr Med Res Opin Subsets: MEDLINE |
| Imprint Name(s): | Publication: 1995- : Newbury, Berkshire, U.K. : Informa Healthcare; Original Publication: London, M. D. Promotions, ltd. |
| MeSH Terms: | Guideline Adherence* ; Practice Guidelines as Topic*; Anticholesteremic Agents/*therapeutic use ; Cholesterol, LDL/*blood ; Coronary Disease/*prevention & control ; Heptanoic Acids/*therapeutic use ; Preventive Health Services/*standards ; Pyrroles/*therapeutic use; Anticholesteremic Agents/administration & dosage ; Cholesterol, LDL/standards ; Coronary Disease/blood ; Coronary Disease/drug therapy ; Heptanoic Acids/administration & dosage ; Pyrroles/administration & dosage ; Atorvastatin ; Europe ; Humans ; Myocardial Infarction ; Societies ; Stroke ; United Kingdom |
| Abstract: | The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study compared two standards (structured vs. usual care) of lipid lowering treatment in 1600 patients with coronary heart disease (CHD). Structured care aimed at achieving (with atorvastatin 10-80 mg) the low-density lipoprotein cholesterol (LDL-C) (2.6 mmol/l; 100 mg/dl) goal described in the NCEP ATP II and III guidelines for patients with CHD. Structured care was associated with a significant reduction in overall mortality and coronary events compared to usual care. In the present brief report we interpret the results of GREACE using the United Kingdom (UK) and European Atherosclerosis Society (EAS) treatment goal for LDL-C in secondary CHD prevention (3.0 mmol/l; 115 mg/dl. The mean dose of atorvastatin decreased from 24 mg to 22 mg/day. More patients achieved the UK and EAS LDL-C target (95.6 vs. 95%) in the structured care arm of the trial; 90% of the patients achieved this target with 10 or 20 mg atorvastatin. These findings may have cost implications, especially if the LDL-C target for high-risk patients will fall below those described above. |
| Substance Nomenclature: | 0 (Anticholesteremic Agents); 0 (Cholesterol, LDL); 0 (Heptanoic Acids); 0 (Pyrroles); A0JWA85V8F (Atorvastatin) |
| Entry Date(s): | Date Created: 20030205 Date Completed: 20030425 Latest Revision: 20260128 |
| Update Code: | 20260130 |
| DOI: | 10.1185/030079902125001317 |
| PMID: | 12564661 |
| Database: | MEDLINE |
Comparative Study; Journal Article